Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Renal cell carcinoma. Found 20 abstracts

Ali N, Kutikov A, Geynisman DM. Resolution of a Debilitating Paraneoplastic Parkinson-like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal Cell Carcinoma. Urol Case Rep. 2017 Sep;14:18-20.   PMCID: PMC5479944
Chen VS, Abouassaly R, Gonzalez CM, Kutikov A, Smaldone MC, Meropol NJ, Psutka SP, Williams SB, O'Malley R, Sedlacek HM, Kim SP. Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort. Urol Oncol. 2017 Aug 03;35(11):662 e17-662 e21.
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. 2017 Dec;72(6):962-71.
Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Current treatment options in oncology. 2017 Jan;18(1):7.
Haifler M, Kutikov A. Update on Renal Mass Biopsy. Current urology reports. 2017 Apr;18(4):28.
Haifler M, Kutikov A. Current Role of Renal Biopsy in Urologic Practice. The Urologic clinics of North America. 2017 May;44(2):203-11.
Kim SP, Campbell SC, Gill I, Lane BR, Van Poppel H, Smaldone MC, Volpe A, Kutikov A. Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. Eur Urol. 2017 Jul;72(1):64-75.
Kim SP, Campbell SC, Gill I, Lane BR, Van Poppel H, Smaldone MC, Volpe A, Kutikov A. Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. Eur Urol. 2017 Jul;72(1):64-75.
Correa AF, Hrebinko RL, Smaldone MC. Management of Recurrent Venous Tumor Thrombus Following Inferior Vena Cava Thrombectomy: Is Surgery the Right Answer?. European urology focus. 2016 Dec 15;2(6):631-2.   PMCID: Editorial
Hawken SR, Krishnan NK, Ambani SN, Montgomery JS, Caoili EM, Ellis JH, Kunju LP, Hafez KS, Miller DC, Kutikov A, Palapattu GS, Weizer AZ, Stuart Wolf J, Morgan TM. Effect of delayed resection after initial surveillance and tumor growth rate on final surgical pathology in patients with small renal masses (SRMs). Urol Oncol. 2016 Nov;34(11):486 e9-486 e15.
Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC nephrology. 2016 Nov 22;17(1):188.   PMCID: PMC5120473
Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer. 2015 Apr;13(2):e93-100.
Mehrazin R, Smaldone MC, Egleston B, Tomaszewski JJ, Concodora CW, Ito TK, Abbosh PH, Chen DY, Kutikov A, Uzzo RG. Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?. Urologic Oncology: Seminars and Original Investigations. 2015 Apr;33(4):167e7-167e12.   PMCID: PMC4417444
Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzburg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 2015 Sep;33(9):388e19-388e25.   PMCID: 4289664
Volpe A, Blute ML, Ficarra V, Gill IS, Kutikov A, Porpiglia F, Rogers C, Touijer KA, Van Poppel H, Thompson RH. Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. Eur Urol. 2015 Jul;68(1):61-74.
Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Invest New Drugs. 2015 Oct;33(5):1040-7.   PMCID: 4573837
Chen DY, Uzzo RG, Viterbo R. Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death. [Review]. World Journal of Urology. 2014 Jun;32(3):607-13.   PMCID: No NIH funding
Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen JH, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer. 2011 Dec;47(18):2706-14.   PMCID: not NIH funded
Touijer K, Jacqmin D, Kavoussi LR, Montorsi F, Patard JJ, Rogers CG, Russo P, Uzzo RG, Van Poppel H. The Expanding Role of Partial Nephrectomy: A Critical Analysis of Indications, Results, and Complications. European Urology. 2010 Feb;57(2):214-22.   PMCID: not NIH funded
Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Medical Oncology . 2009 Jan;26(2):202-9.   PMCID: not NIH funded
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Renal cell carcinoma

Renal cell carcinoma Kidney Neoplasms Partial nephrectomy Surgery Female pathology Renal Cell Carcinoma Male Renal mass Radical nephrectomy Aged Nivolumab Nephron-sparing surgery Middle Aged Renal masses Biopsy Immunotherapy Kidney cancer interferon-alpha Paraneoplastic syndrome Lymphopenia KIDNEY CANCER RISING Case report Programmed death 1 Acute kidney injury long-term survival Tumor Burden Neoplasm Metastasis Surveillance complications Urology & Nephrology Biomarker Accuracy Inflammatory disease INCIDENCE Healthcare Disparities radical nephrectomy laparoscopic partial Positive margins Cohort Studies Kaplan-Meier Estimate Cost-Benefit Analysis Insurance Claim Review Diagnosis Delayed intervention Autoimmune nephritis HDAC inhibition mTOR inhibition Immune checkpoint inhibitor Immune checkpoint blockade Sunitinib Adult Renal function Phase 3 SURVIVAL normal contralateral kidney TUMORS Disease Progression Differential Diagnosis surgery Race 80 and over Aged Tumor histology Lymphocyte count Angiogenesis inhibitors Active surveillance Prognostic measurement CO-MORBIDITY mortality Proportional Hazards Models Everolimus ACTIVE SURVEILLANCE oncological outcomes Papillary renal cell carcinoma Treatment patterns Cytotoxic T-lymphocyte associated protein 4 Medical decision making Renal tumor Nephrometry Score CHARLSON COMORBIDITY INDEX Venous tumor thrombus methods survival Nomogram Renal tumours Robotic partial nephrectomy Prognosis Tyrosine kinase inhibitor therapy Survival NATURAL-HISTORY Urological Diagnostic Techniques immunology carcinoma Local recurrence renal-cell carcinoma MASSES nephrectomy iii trial positive surgical margins Watchful Waiting Nephrectomy economics Ischemia Renal neoplasms SEER VALIDATION Interferon-alpha Drug Costs Papillary Tumor complexity Surgical management Vegf 10-year follow-up nephron-sparing surgery 4 cm ABT-869 Comorbidity double-blind Oral anticancer medications Clinical Decision-Making drug therapy VEGFR Antineoplastic agents Factual Databases Growth kinetics Logistic Models Temsirolimus mTOR resistance
Last updated on Friday, January 05, 2018